|
MechanismRespiratory syncytial virus F protein inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Sequential-Cohort, Double-Blind, Placebo-Controlled, Multiple Ascending Oral Dose Study of the Safety and Pharmacokinetics of BTA-C585 in Healthy Volunteers
This is a single center, sequential-cohort, double-blind, placebo-controlled, multiple ascending dose (MAD), 7-day treatment period study in healthy subjects.
A Double-Blind, Placebo-Controlled, Single Ascending Oral Dose Study of the Safety and Pharmacokinetics of BTA-C585 in Healthy Volunteers
This is a placebo-controlled, double-blind, randomized, single dose escalation Phase 1 clinical trial to determine the safety and tolerability of BTA-C585 administered orally to healthy subjects.
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults with Symptomatic Human Rhinovirus Infection. - Phase 2 Asthma
100 Clinical Results associated with Biota Pharmaceuticals, Inc. /Antibiotics Assets/
0 Patents (Medical) associated with Biota Pharmaceuticals, Inc. /Antibiotics Assets/
100 Deals associated with Biota Pharmaceuticals, Inc. /Antibiotics Assets/
100 Translational Medicine associated with Biota Pharmaceuticals, Inc. /Antibiotics Assets/